

February 16, 2026

Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP)

Company name: Japan Animal Referral Medical Center (JARMeC)
 Listing: Tokyo Stock Exchange
 Securities code: 6039
 URL: <https://www.jarmec.co.jp>
 Representative: Hidehiro Hirao, Representative Director and President
 Inquiries: Masami Oe, Executive Director and Head of Corporate Administration
 Telephone: +81-44-850-1320
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended								
December 31, 2025	4,660	18.2	966	63.8	962	63.0	675	65.0
December 31, 2024	3,942	26.5	590	70.8	590	76.2	409	85.5

Note: Comprehensive income For the nine months ended December 31, 2025: ¥675 million [65.0%]
 For the nine months ended December 31, 2024: ¥409 million [85.5%]

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Nine months ended				
December 31, 2025	52.24		-	
December 31, 2024	31.57		31.51	

Note: 1. Quarterly net income per share adjusted for potential shares for the third quarter of the fiscal year ending March 31, 2026 is not included because there are no potential shares.

2. On December 17, 2025, the Company conducted a share split at a ratio of 5 shares per share of common shares. "Basic earnings per share" and "diluted earnings per share" are calculated on the assumption that the said share split was conducted at the beginning of the previous fiscal year.

(2) Consolidated financial position

	Total assets		Net assets		Equity-to-asset ratio	
	Millions of yen		Millions of yen		%	
As of						
December 31, 2025	9,265		4,723		51.0	
March 31, 2025	8,753		4,148		47.4	

Reference: Equity
 As of December 31, 2025: ¥4,723 million
 As of March 31, 2025: ¥4,148 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	-	0.00	-	37.00	37.00
Fiscal year ending March 31, 2026	-	0.00	-		
Fiscal year ending March 31, 2026 (Forecast)				8.00	8.00

Note: Revisions to the forecast of cash dividends most recently announced: None

2. On December 17, 2025, the Company conducted a share split at a ratio of 5 shares per share of common shares. Dividends per share for the fiscal year ending March 31, 2025 are the actual amount of dividends before the stock split.

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2026	6,100	15.6	1,040	44.2	1,030	43.0	730	40.1	56.48

Note: Revisions to the earnings forecasts most recently announced: None

2. On December 17, 2025, the Company conducted a share split at a ratio of 5 shares per share of common shares. Assuming that the stock split occurred at the beginning of the current fiscal year, "net income per share" is calculated.

*4. Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

Note: For details, see "2. Quarterly Consolidated Financial Statements and Key Notes (3) Notes on Quarterly Consolidated Financial Statements (Notes on Accounting Procedures Specific to the Preparation of Quarterly Consolidated Financial Statements)" are available.

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	14,391,000 shares
As of March 31, 2025	14,391,000 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2025	1,466,710 shares
As of March 31, 2025	1,467,210 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Nine months ended December 31, 2025	12,923,969 shares
Nine months ended December 31, 2024	12,960,729 shares

Note: 1. The number of treasury shares at the end of the fiscal year and the number of treasury shares to be deducted for the calculation of the average number of shares during the period include the Company's shares held by the J-ESOP Trust Account.

2. On December 17, 2025, the Company conducted a share split at a ratio of 5 shares per share of common shares. "Total number of issued shares at the end of the period," "number of treasury shares at the end of the period," and "average number of shares outstanding during the period" are calculated on the assumption that the said share split was conducted at the beginning of the previous fiscal year.

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts, and other special matters

- The forward-looking statements, including forecasts of financial results, contained in these materials are based on information available to the Company and on certain assumptions deemed to be reasonable. Actual financial results may differ from the results anticipated in the statements due to various factors. Matters related to the above earnings forecasts are described in the attached document "1. Summary of Operating Results, etc. (3) Explanation of Forward-Looking Information such as Consolidated Earnings Forecasts."

Quarterly consolidated balance sheet

(Thousands of yen)

	As of March 31, 2025	As of December 31, 2025
Assets		
Current assets		
Cash and deposits	1,107,603	1,223,136
Accounts receivable - trade, and contract assets	326,076	408,196
Merchandise and finished goods	75,960	92,776
Raw materials and supplies	18,748	22,482
Other	76,484	94,080
Allowance for doubtful accounts	(6,876)	(9,458)
Total current assets	1,597,996	1,831,214
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	2,280,603	2,200,142
Tools, furniture and fixtures, net	1,690,749	1,705,258
Land	2,340,355	2,483,574
Other, net	5,101	211,719
Total property, plant and equipment	6,316,808	6,600,695
Intangible assets		
Goodwill	142,588	127,311
Trademark right	304,824	272,165
Other	32,007	65,328
Total intangible assets	479,420	464,805
Investments and other assets	359,492	369,177
Total non-current assets	7,155,722	7,434,678
Total assets	8,753,719	9,265,892

	As of March 31, 2025	As of December 31, 2025
Liabilities		
Current liabilities		
Accounts payable - trade	65,768	87,905
Accounts payable - other	217,574	328,155
Short-term borrowings	-	69,000
Current portion of long-term borrowings	627,165	644,099
Income taxes payable	205,029	176,867
Provision for bonuses	182,483	78,935
Other	256,151	303,375
Total current liabilities	1,554,172	1,688,338
Non-current liabilities		
Long-term borrowings	2,847,886	2,637,872
Provision for share awards	33,831	56,726
Retirement benefit liability	46,200	50,500
Deferred tax liabilities	76,565	65,269
Asset retirement obligations	41,851	43,729
Other	4,684	416
Total non-current liabilities	3,051,019	2,854,513
Total liabilities	4,605,192	4,542,852
Net assets		
Shareholders' equity		
Share capital	801,600	801,600
Capital surplus	720,405	720,405
Retained earnings	3,179,791	3,754,108
Treasury shares	(553,270)	(553,074)
Total shareholders' equity	4,148,527	4,723,040
Total net assets	4,148,527	4,723,040
Total liabilities and net assets	8,753,719	9,265,892

Quarterly consolidated statement of income

(Thousands of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Net sales	3,942,127	4,660,153
Cost of sales	2,531,432	2,752,902
Gross profit	1,410,694	1,907,250
Selling, general and administrative expenses	820,486	940,436
Operating profit	590,207	966,814
Non-operating income		
Rental income from buildings	18,094	18,094
Other	4,997	11,191
Total non-operating income	23,091	29,286
Non-operating expenses		
Interest expenses	18,562	25,867
Financing expenses	2,892	2,222
Loss on retirement of non-current assets	1,030	3,365
Other	120	1,672
Total non-operating expenses	22,606	33,127
Ordinary profit	590,692	962,972
Extraordinary income		
Gain on sale of non-current assets	18	-
Total extraordinary income	18	-
Profit before income taxes	590,710	962,972
Income taxes	181,503	287,700
Profit	409,207	675,272
Profit attributable to owners of parent	409,207	675,272

Quarterly consolidated statement of comprehensive income

(Thousands of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Profit	409,207	675,272
Comprehensive income	409,207	675,272
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	409,207	675,272